The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Managing accelerated- and blast-phase MPNs in fit and unfit patients
Vikas Gupta, MD, FRCP, FRCPath, Princess Margaret Cancer Centre, Toronto, Canada, discusses the management of accelerated- and blast-phase myeloproliferative neoplasms (MPNs) in transplant-eligible and transplant-ineligible patients. Dr Gupta explores treatment strategies including hypomethylating agents, venetoclax and allogeneic stem cell transplantation, highlighting the need for disease-specific response criteria and improved clinical trial design. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
